Prostate Cancer Clinical Trial
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Summary
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy. The effects will be monitored on a weekly basis by measuring various markers of bone metabolism. Patients to be enrolled will be those who have not received any previous bisphosphonate therapy. The study will be carried out on prostate cancer patients who are no longer on hormone therapy. Treatment in the study will be for a 2-month period.
Eligibility Criteria
Inclusion Criteria:
Prostate Cancer with rising PSA levels after hormone treatment and bone metastasis based on an X-ray.
Exclusion Criteria:
Already be on a bisphosphonate treatment (Zometa, Fosamax, Actonel)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Birmingham Alabama, 35223, United States
Lake City Florida, 32055, United States
Lakeland Florida, 33805, United States
Miami Florida, 33179, United States
Ruston Louisiana, 71270, United States
New York New York, 10022, United States
Charleston South Carolina, 29403, United States
Abingdon Virginia, 24211, United States
Tallinn , , Estonia
Tallinn , , Estonia
Tartu , , Estonia
Daugavpils , , Latvia
Riga , , Latvia
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.